drugset / Trial / NCT00866554
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine if a combination of neoadjuvant dutasteride and bicalutamide has the same efficacy and less toxicity than standard treatment with an LHRH agonist and bicalutamide for prostate cytoreduction prior to permanent implant brachytherapy.
Timeline
- Start
- 2009-03
- Primary completion
- 2019-03
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bicalutamide | Other / unclassified | 50 mg | — |
| Subject | Dutasteride | Small molecule | 0.5 mg | — |
| Subject | Tamoxifen | Small molecule | 10 mg | — |